catecholamine resistant Hypotension

Shares of La Jolla Pharmaceutical Company (NASDAQ: LJPC) were trading lower by more than 8 percent Monday morning after the company released Phase 3 results in the New England Journal of Medicine from a study called ATHOS-3, which evaluated the company's therapy LJPC-501 for the treatment of...